Drug Profile


Alternative Names: BAY-2306001; FXI ASO; ISIS 404071; ISIS-416858; ISIS-FXIRX

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Bayer; Ionis Pharmaceuticals
  • Class Anticoagulants; Antisense oligonucleotides; Antithrombotics
  • Mechanism of Action Factor XI inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Thrombosis; Venous thromboembolism

Most Recent Events

  • 11 Dec 2017 Ionis Pharmaceuticals plans to initiate a phase II pharmacokinetics and pharmacodynamics trial (In adults, In the elderly) in Austria, Belgium, Bulgaria, Canada, Czech Republic, Netherlands, Spain (SC) (NCT03358030) (EudraCT2017-002165-21)
  • 09 Dec 2017 Safety, pharmacokinetics and pharmacodynamics data from a phase II trial in Thromboses presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
  • 01 Dec 2017 Phase-II clinical trials in Thrombosis (In adults, In the elderly) in Spain, Austria (SC) (NCT03358030) (EudraCT2017-002165-21)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top